MERCK IS DIRT CHEAP. $11 BILLION CANCER DRUG. SALES BOOMING!
We keep seeing Clinical Stage Companies that are publicly traded, with new FDA Approvals, and the stocks are blasting off. Many of those are trading over $100 with no revenue, profits or earnings.
Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street Corruption at it's best!
We took a long position at $82.00 several weeks ago.
We feel the stock is worth at minimum, $150.00 all day long.
KEYTRUDA alone, not counting any other products manufactured / developed by Merck, or any other divisions of Merck, is forecast to bring in over $11 Billion in sales.
Holding for the almost 3% Dividend and for the stock price appreciation into the future.
250,000 LONG @ $82.00
Best of Luck Everyone!
Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street Corruption at it's best!
We took a long position at $82.00 several weeks ago.
We feel the stock is worth at minimum, $150.00 all day long.
KEYTRUDA alone, not counting any other products manufactured / developed by Merck, or any other divisions of Merck, is forecast to bring in over $11 Billion in sales.
Holding for the almost 3% Dividend and for the stock price appreciation into the future.
250,000 LONG @ $82.00
Best of Luck Everyone!
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.